Provided by Tiger Trade Technology Pte. Ltd.

LivaNova PLC

63.30
+0.90001.44%
Post-market: 63.300.00000.00%17:19 EDT
Volume:532.51K
Turnover:33.57M
Market Cap:3.46B
PE:-14.22
High:63.65
Open:63.24
Low:61.62
Close:62.40
52wk High:71.92
52wk Low:32.48
Shares:54.61M
Float Shares:54.41M
Volume Ratio:0.63
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4500
EPS(LYR):-4.4500
ROE:-19.24%
ROA:5.17%
PB:2.88
PE(LYR):-14.22

Loading ...

Assessing LivaNova (LIVN)’s Valuation After Hiring ResMed Veteran to Lead Sleep Apnea Commercialization

Simply Wall St.
·
Dec 15, 2025

The Bull Case For LivaNova (LIVN) Could Change Following Medicare VNS Boost And New OSA Leader

Simply Wall St.
·
Dec 09, 2025

LivaNova Highlights CORE-VNS Study Showing VNS Therapy Reduces Seizure Frequency and Healthcare Costs in Drug-Resistant Epilepsy

Reuters
·
Dec 03, 2025

LivaNova Names Lucile Blaise Global Head of Commercialization for Obstructive Sleep Apnea

Reuters
·
Dec 02, 2025

LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea

THOMSON REUTERS
·
Dec 02, 2025

LivaNova CFO to Present Business Update at Piper Sandler Healthcare Conference

Reuters
·
Nov 25, 2025

LivaNova Shares Hit 52-Week High After VNS Therapy Gets Increased Payment Classification

Dow Jones
·
Nov 24, 2025

LivaNova receives increased CMS reimbursement for VNS Therapy

TIPRANKS
·
Nov 24, 2025

LivaNova Plc - Hospital Payments to Rise 48% for Npis, 47% for Eos From 2026

THOMSON REUTERS
·
Nov 24, 2025

LivaNova Plc - Reimbursement for Vns Therapy Dre Procedures to Increase in 2026

THOMSON REUTERS
·
Nov 24, 2025

LivaNova’s Vns Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement From U.S. Centers for Medicare & Medicaid Services

THOMSON REUTERS
·
Nov 24, 2025

LivaNova Director Brooke Story Reports Sale of Common Shares

Reuters
·
Nov 20, 2025

LivaNova Q3 Adjusted EPS USD 1.11 Vs. IBES Estimate USD 0.92

Reuters
·
Nov 20, 2025

LivaNova Is Maintained at Outperform by Baird

Dow Jones
·
Nov 13, 2025

Mizuho Securities Remains a Buy on LivaNova (LIVN)

TIPRANKS
·
Nov 13, 2025

LivaNova Plc : Mizuho Raises Target Price to $70 From $65

THOMSON REUTERS
·
Nov 13, 2025

Barclays Sticks to Their Hold Rating for LivaNova (LIVN)

TIPRANKS
·
Nov 13, 2025

LivaNova Sees High Single-Digit Sales Growth by 2030

Dow Jones
·
Nov 13, 2025

LivaNova introduces 2030 financial targets at Investor Day

TIPRANKS
·
Nov 13, 2025

Stock Track | LivaNova Soars 8.74% as Strategic Roadmap Promises Strong Growth and Margin Expansion by 2030

Stock Track
·
Nov 13, 2025